Evaluation of adverse events focusing on infection associated with infliximab originator and biosimilar using a spontaneous reporting system database | Journal of Pharmaceutical Health Care and Sciences | Full Text

Evaluation of adverse events focusing on infection associated with infliximab originator and biosimilar using a spontaneous reporting system database | Journal of Pharmaceutical Health Care and Sciences | Full Text

Journal of Pharmaceutical Health Care and Sciences

Evaluation of adverse events focusing on infection associated with infliximab originator and biosimilar using a spontaneous reporting system database

Infliximab (IFX) has changed the management of many life-threatening immune-mediated diseases. The high cost of IFX and its patent expiry have led to pharmaceutical companies developing a biosimilar; however, ...

Authors:Iku Niinomi, Keiko Hosohata, Yasuhiro Mori, Yuki Yamaguchi, Tomohito Wakabayashi, Mayako Uchida and Kazunori Iwanaga

Citation:Journal of Pharmaceutical Health Care and Sciences 2019 5:21

Content type:Short report

Published on: 7 October 2019

• ViewFull Text
 
• ViewPDF